[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Consorci Sanitari de l'Alt Penedès i Garraf\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":467},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,42,66,92,113,142,166,188,211,238,259,284,309,334,357,381,401,428,447],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100614365","high-risk-antithrombotic-drugs-at-discharge-and-consultation-for-hemorrhagic-or-thromboembolic-events-in-the-emergency-department-100614365",false,"NCT07278648","High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department","Prescription of High-risk Antithrombotic Drugs at Discharge and Consultation for Hemorrhagic or Thromboembolic Events in the Emergency Department. Retrospective Cohort Study","Inclusion Criteria:\n\n* Patients discharged from the Emergency Department (ED) and acute care units with an electronic prescription for at least one anticoagulant medication (new or ongoing), identified with the following codes:\n\nB01AA - Vitamin K antagonists: warfarin and acenocoumarol\n\nB01AB - Heparin group: low-molecular weight heparins such as enoxaparin, tinzaparin, bemiparin, …\n\nB01AE - Direct thrombin inhibitors: dabigatran\n\nB01AF - Direct factor Xa inhibitors: rivaroxaban, apixaban, edoxaban\n\nExclusion Criteria:\n\n* Those who are not part of the CSAPG healthcare area.\n* Patients discharged from outpatient clinics, home hospitalization units, intermediate care, or residential facilities.","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","OBSERVATIONAL","This observational study aims to estimate the proportion of patients discharged from a hospital with a prescription for anticoagulant medication who subsequently visit the emergency department due to an adverse thrombotic or hemorrhagic event related to the treatment.",[24],"Acute Disease",[26,27,28],"Antithrombotic Treatment","Hemorragic Event","Anticoagulants","NOT_YET_RECRUITING","2025-12-18",{"date":32,"type":33},"2025-12-24","ACTUAL",{"date":35,"type":20},"2026-02-05",{"date":37,"type":20},"2026-03-01",{"name":39,"class":40},"Consorci Sanitari de l'Alt Penedès i Garraf","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100614879","dietitian-nutritionist-vs-day-hospital-in-the-metabolic-control-of-patients-with-type-2-diabetes-100614879","NCT07285330","Dietitian-Nutritionist vs. Day Hospital in the Metabolic Control of Patients With Type 2 Diabetes","NUTRI-DIAB: Impact of the Dietitian-Nutritionist Model vs. Day Hospital on the Metabolic Control of Patients With Type 2 Diabetes","NUTRI-DIAB","Inclusion Criteria:\n\n* Patients with a diagnosis of type 2 diabetes (T2DM) referred to endocrinology due to poor metabolic control.\n* Patients on insulin therapy\n\nExclusion Criteria:\n\n* Referred from primary care for other reasons such as hypoglycemia.\n* Patients with other types of diabetes mellitus or with uncertainty in diagnostic classification.\n* Patients on rapid-acting insulin bolus therapy.\n* Patients with acute decompensation of diabetes.\n* Patients receiving corticosteroid treatment.\n* Dependent individuals for activities of daily living (ADL) with a Barthel index score below 60 or with cognitive impairment.\n* Language barrier.",{"count":51,"type":20},140,"The present study aims to compare the effects on glycated hemoglobin (HbA1c) at 3 months of two care models in patients with type 2 diabetes referred due to poor glycemic control: a day hospital endocrinology care model versus a care model centered on follow-up by a dietitian-nutritionist.",[54],"Diabetes (DM)",[56],"Diabetes Mellitus","RECRUITING","2025-12-03",{"date":60,"type":33},"2025-12-16",{"date":62,"type":33},"2025-06-30",{"date":64,"type":20},"2026-04-30",{"name":39,"class":40},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":41},"100509972","radiofrequency-ablation-for-the-treatment-of-post-knee-arthroplasty-chronic-pain-100509972","NCT05920382","Radiofrequency Ablation for the Treatment of Post-knee Arthroplasty Chronic Pain.","Radiofrequency Ablation for the Treatment of Post-knee Arthroplasty Chronic Pain. A Randomized Double-blind Study. A Novel Approach.","CSAPG-37","Inclusion Criteria:\n\n* Individuals who have undergone knee arthroplasty.\n* Chronic knee pain post-knee arthroplasty for at least 6 months after the procedure and less than 5 years.\n* Pain intensity on the numerical visual scale ≥ 5 out of 10 points.\n* Stable pain for the last 30 days.\n* The knee is the location with the highest intensity of pain, in the case of patients with multiple joint pains.\n\nExclusion Criteria:\n\n* Acute knee pain.\n* Psychiatric illness or dementia that may interfere with or hinder study assessments.\n* Diagnosis of fibromyalgia, chronic fatigue syndrome, or central sensitization syndrome.\n* Knee infiltration with corticosteroids in the past 30 days.\n* Changes in oral analgesic medication in the past 30 days.",{"count":75,"type":20},86,"INTERVENTIONAL",[78],"NA","Knee osteoarthritis pain is one of the conditions commonly seen in general and specialized medicine. Knee arthroplasty is one of the most successful orthopedic surgeries for the treatment of this disease, significantly improving pain, disability, and the overall quality of life for patients who undergo it. However, there is a subgroup of individuals in whom the pain persists or even worsens. Radiofrequency has been introduced over 10 years ago as a neuroablative technique targeting the genicular nerves, which innervate the sensory terminals of the knee joint, for the treatment of chronic pain in that region before or after arthroplasty. However, the results have not been entirely consistent. Recent anatomical studies have demonstrated the presence of other sensory terminal branches of the femoral nerve, such as the infrapatellar branch of the saphenous nerve, medial vastus nerve, intermediate vastus nerve, and lateral vastus nerve, which could be useful targets for the treatment of post-knee arthroplasty pain. To date, no studies have been conducted to address post-knee arthroplasty pain through the application of thermal radiofrequency on the sensory branches of the knee from the femoral nerve (infrapatellar branch of the saphenous nerve, medial vastus nerve, intermediate vastus nerve, lateral vastus nerve). Therefore, The investigators aim to conduct a randomized double-blind clinical trial where The investigators will apply thermal radiofrequency on the sensory terminal branches of the femoral nerve in the knee, based on recent anatomical studies. The objective of the study is to determine if radiofrequency ablation of sensory nerves in the knee improves pain and disability in patients with post-knee arthroplasty chronic pain at the L'Alt Penedés-Garraf Health Consortium. Method: This is a randomized double-blind clinical trial with two arms. Two groups will be used, where one group will receive thermal radiofrequency of sensory nerves in the knee, and the other group will receive a placebo treatment. The hypothesis The investigators propose is that radiofrequency ablation will alleviate at least 50% of baseline pain and disability in at least 50% of the patients.",[81,82,83],"Chronic Post-surgical Pain","Chronic Post Operative Pain","Chronic Knee Pain","2025-12-02",{"date":86,"type":33},"2025-12-09",{"date":88,"type":33},"2023-09-25",{"date":90,"type":20},"2027-12-01",{"name":39,"class":40},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":41},"100593493","is-a-positive-necpal-in-icu-patients-associated-with-higher-mortality-100593493","NCT07007156","Is a Positive NECPAL in ICU Patients Associated With Higher Mortality","Inclusion Criteria:\n\n* Patients who meet all of the following inclusion criteria may be included in the study:\n* Men and women aged 75 years or older.\n* Admission to the ICU of the study center.\n* Legal capacity to provide informed consent.\n* Signed informed consent for study inclusion, either by the participant or their legal representative.\n\nExclusion Criteria:\n\nParticipants who meet any of the following exclusion criteria may not be included in the study:\n\n-Death within the first 24 hours of ICU admission.","75 Years",{"count":100,"type":20},199,"The aim of the present study is to evaluate the usefulness of the NECPAL scale in identifying Intensive Care Unit (ICU)-admitted patients at higher risk of dying within 90 days of ICU admission",[24],[24,104],"Intensive Care Unit","2025-12-01",{"date":107,"type":33},"2025-12-05",{"date":109,"type":33},"2025-06-12",{"date":111,"type":20},"2027-01",{"name":39,"class":40},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":120,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":76,"phases":123,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":135,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},"100593569","introducing-electronic-alerts-to-reduce-inappropriate-digoxin-prescribing-in-older-adults-100593569","NCT07008144","Introducing Electronic Alerts to Reduce Inappropriate Digoxin Prescribing in Older Adults","Aldigo","Inclusion Criteria:\n\n* Men and women over 64 years of age.\n* Hospitalized in inpatient wards of the study centers during the study period.\n\nExclusion Criteria:\n\n* Pacients under 64 years old\n* Patients without complete data available","65 Years",{"count":122,"type":20},5954,[78],"The intervention consists of introducing computerized alerts into the electronic medical record of the CSAPG (MIRA software), which are triggered when a physician prescribes digoxin at a dose higher than the recommended amount (more than 0.125 mg\u002Fday).\n\nThe main objective of this study is to evaluate the effectiveness of a visible computerized alert aimed at physicians responsible for hospitalized elderly patients who have been prescribed digoxin at a dose higher than 0.125 mg\u002Fday (the recommended dose), in reducing the number of patients receiving inappropriate digoxin doses.",[126,127],"Drug-Related Side Effects and Adverse Reaction","Digoxin Overdose",[129,130,131,132,133,134],"digoxin","deprescription","Beers","computerized alerts","geriatrics","Elderly Hospitalized Patients",{"date":84,"type":33},{"date":137,"type":20},"2025-12",{"date":139,"type":20},"2026-11-30",{"name":39,"class":40},2,{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},"100572026","predictive-model-for-mortality-in-older-people-with-critical-illness-100572026","NCT06727903","Predictive Model for Mortality in Older People With Critical Illness","Development of a Predictive Model for Mortality in Patients Aged 75 or Older With Critical Illness","VITA","Inclusion Criteria:\n\n* Men and women aged 75 or older.\n* Admission to an ICU from the Emergency Department.\n* Availability of or possibility to contact a participant's informant.\n* Informed consent for participation in the study, either by the participant or a valid legal representative.\n\nExclusion Criteria:\n\nParticipants meeting any of the following exclusion criteria will not be included in the study:\n\n* Patients transferred to the Emergency Department from a hospital ward.\n* Patients who die within the first 24 hours of ICU admission.\n* Patients admitted to Step-Down Units.\n* Patients requiring ICU admission for any of the following reasons:\n\nOrotracheal intubation or advanced cardiopulmonary resuscitation performed prior to arrival at the Emergency Department.\n\nAV block awaiting pacemaker implantation. Activation of the STEMI or Stroke care pathway. Post-cardiac catheterization for acute coronary syndrome.\n\n* Participation in another clinical study involving an intervention, procedure, or visit schedule that is incompatible with the present study.",{"count":151,"type":20},450,"The present study aims to develop a predictive model to identify elderly patients with the highest likelihood of mortality upon admission to an intensive care unit.",[154],"Critical Illness",[154,156,157,158],"Mortality","Aged","Intensive Care Units",{"date":84,"type":33},{"date":161,"type":33},"2025-03-20",{"date":163,"type":20},"2026-12",{"name":39,"class":40},15,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":41},"100556624","prevalence-of-amyloidosis-in-trauma-patients-100556624","NCT06527521","Prevalence of Amyloidosis in Trauma Patients","Prevalence of Amyloidosis in Trauma Patients Using Red Flags Tool","APTUR","Inclusion Criteria:\n\n* Men and women included in the waiting list for scheduled trauma surgery with at least one of the following criteria defined as red flags: Over 65 years old; Possible family history of amyloidosis, Cardiac pathology: aortic stenosis, presence of left ventricular hypertrophy defined as interventricular septal thickness \\> 12mm measured by echocardiography, history of previous brady- or tachyarrhythmias including cardiac conduction blocks, history of syncope or presyncope, pro BNP \\> 300 in previous blood tests; History of sensory peripheral neuropathy; History of nephropathy without etiological diagnosis; History of liver disease without a clear cause.\n* Ability to cooperate in the necessary evaluations.\n* Signed informed consent for inclusion in the study, either by the participant or their legal representative.\n\nExclusion Criteria:\n\n\\- Participants previously diagnosed with amyloidosis cannot be included in the study.",{"count":175,"type":20},246,"This study aims to determine the frequency of amyloidosis among patients undergoing trauma surgery.",[178],"Amyloidosis",[178,180,181],"Red Flags tool","Traumatology",{"date":84,"type":33},{"date":184,"type":33},"2024-11-13",{"date":186,"type":20},"2026-10",{"name":39,"class":40},{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":76,"phases":198,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":41},"100540361","levels-of-diagnostic-and-therapeutic-intervention-in-hospitalized-patients-100540361","NCT06315842","Levels of Diagnostic and Therapeutic Intervention in Hospitalized Patients","Levels of Diagnostic and Therapeutic Intervention in Hospitalized Patients. Cluster-Randomized and Stepped-Wedge Clinical Trial","NIT","Inclusion Criteria:\n\n* Physician belonging to the non-surgical medical area.\n* Routine clinical activity on a hospital ward caring for hospitalized patients.\n\nExclusion Criteria:\n\n* Physician belonging to the Oncology-Hematology\u002FPalliative Care Hospitalization Unit.\n* Refusal to participate in the study.",{"count":197,"type":20},20,[78],"The objective of this clinical trial is to investigate the impact of implementing a tool for adjusting the level of diagnostic and therapeutic intensity in the clinical practice of physicians attending hospitalized patients.\n\nThe goal of this clinical trial is to investigate the impact of a tool for adjusting diagnostic and therapeutic intensity in hospitalized patients. The main question it aims to answer is: Is there a difference in patient mortality when using the aforementioned tool? The participating physicians will be grouped into 4 groups (5 physicians each). Each group will progressively (every 3 months) incorporate the use of the aforementioned tool into their usual clinical practice.",[24],[202,203,204],"Patient Care Planning","Decision Making","Advance Care Planning",{"date":107,"type":33},{"date":207,"type":20},"2026-02",{"date":209,"type":20},"2027-08",{"name":39,"class":40},{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":219,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":222,"conditions":223,"keywords":227,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":41},"100609237","loneliness-as-risk-factor-for-dementia-100609237","NCT07211945","Loneliness as Risk Factor for Dementia","Loneliness as a Risk Factor for Dementia in Patients With Mild Cognitive Impairment: A Prospective Study","SOLETE","Inclusion criteria\n\nPatients may be included in the study if they meet all of the following criteria:\n\nMen and women aged 70 years or older.\n\nDiagnosis of mild cognitive impairment according to Petersen's criteria within the past 12 months.\n\nFollow-up of the condition under study at the Alzheimer's Disease and Other Dementias Unit of Garraf (UMAG) at the Consorci Sanitari Alt Penedès-Garraf (CSAPG).\n\nExpected follow-up of the condition at the study center.\n\nAbility to collaborate in the required assessments.\n\nLegal capacity to provide informed consent.\n\nSigned informed consent for inclusion in the study, either by the participant or their legal representative.\n\nExclusion criteria\n\nParticipants will be excluded from the trial if they meet any of the following criteria:\n\nDiagnosis of any of the following conditions:\n\nDementia: the evaluating physician will rely on the diagnostic criteria of the Spanish Society of Neurology (SEN) and the results of the neuropsychological assessment performed at the UMAG.\n\nParticipation in another study involving an experimental intervention during the present trial period and\u002For requiring a visit schedule incompatible with this trial.","70 Years",{"count":221,"type":20},300,"This study aims to determine whether loneliness is associated with a higher incidence of dementia in older adults with a prior diagnosis of mild cognitive impairment after 12 months of follow-up.",[224,225,226],"Mild Cognitive Impairment (MCI)","Dementia (Diagnosis)","Loneliness",[228,229,226],"Cognitive Dysfunction","Dementia","2025-11-21",{"date":232,"type":33},"2025-11-26",{"date":234,"type":20},"2026-03",{"date":236,"type":20},"2028-09",{"name":39,"class":40},{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":245,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":256,"leadSponsor":257,"locationsCount":258},"100609236","tofacitinib-in-juvenile-idiopathic-arthritis-100609236","NCT07211932","Tofacitinib in Juvenile Idiopathic Arthritis","Efficacy of Tofacitinib in Patients With Juvenile Idiopathic Arthritis: A Study Based on Real-world Clinical Practice Data.","Inclusion criteria:\n\nDiagnosis of juvenile idiopathic arthritis (JIA) documented in the medical record by the treating rheumatologist.\n\nDocumentation in the medical record of the medical indication for tofacitinib treatment, with a diagnostic justification related to JIA.\n\nAge under 18 years at the time of the treatment indication with tofacitinib.\n\nExclusion criteria:\n\nParticipants diagnosed with any of the following conditions:\n\nReactive arthritis\n\nArthritis associated with inflammatory bowel disease\n\nArthritis associated with another autoimmune disease",{"count":246,"type":20},58,"This study aims to evaluate, using real-world clinical practice data, the efficacy of tofacitinib in improving the clinical control of juvenile idiopathic arthritis (JIA) after 12 months of treatment.",[249],"Juvenile Idiopathic Arthritis (JIA)",[251,252,253],"Arthritis, Juvenile","tofacitinib [Supplementary Concept]","Janus Kinase Inhibitors",{"date":232,"type":33},{"date":137,"type":20},{"date":163,"type":20},{"name":39,"class":40},3,{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":270,"conditions":271,"keywords":273,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":41},"100551971","informative-exhibition-for-deprescribing-benzodiazepines-100551971","NCT06467019","Informative Exhibition for Deprescribing Benzodiazepines","Impact of an Interactive and Informative Exhibition on Benzodiazepine Use on Deprescription.","ESUB","Inclusion Criteria:\n\n* Men and women between 18 and 99 years of age.\n* Attended at the Baix-a-Mar Primary Care Center during the study period.\n\nExclusion Criteria:\n\n* Severe mental health disease\n* Displaced patients or those who do not have an assigned doctor at the center.\n* Participation in another study involving an experimental intervention during the period of the present study that affects benzodiazepine prescription.","99 Years",{"count":269,"type":20},6410,"The goal of this trial is to determine if an interactive and informative exhibition in the waiting room of a Primary Care Clinic can reduce the use of benzodiazepines in adults. The main question it aims to answer is:\n\n• Does an interactive and informative exhibition reduce the number of participants using benzodiazepines? Researchers will compare benzodiazepine consumption before and after the interactive and informative exhibition implementation at study center.\n\nParticipants will receive an informative and interactive exhibition on the risks of chronic benzodiazepine use. A single informative session on the same topic will be conducted for health professionals.",[272],"Benzodiazepine-Related Disorders",[274,275],"Benzodiazepines","Deprescriptions","2025-06-23",{"date":278,"type":33},"2025-06-26",{"date":280,"type":33},"2024-06-13",{"date":282,"type":20},"2026-07",{"name":39,"class":40},{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":16,"minAge":292,"maxAge":293,"enrollmentInfo":294,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":296,"conditions":297,"keywords":301,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":304,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":308,"locationsCount":41},"100545186","tapping-test-and-the-archimedean-spiral-for-the-differential-diagnosis-of-tremor-machine-learning-approach-100545186","NCT06378619","Tapping Test and the Archimedean Spiral for the Differential Diagnosis of Tremor. Machine Learning Approach","Machine Learning Analysis Of The Tapping Test And The Archimedean Spiral For The Differential Diagnosis Of Essential Tremor And Parkinson's Disease.","MATSEP","Inclusion Criteria:\n\n* Possibility to collaborate in the necessary evaluations.\n* Follow-up in the specialized consultation of Movement Disorders at the Neurology Service of Hospital Sant Camil-Consorci Sanitari Alt Penedes i Garraf.\n* Legal capacity to provide informed consent.\n* Signature of informed consent for study inclusion, either by the participant themselves or by their legal representative.\n* Participant with criteria from Group 1 or 2:\n\nGroup 1:\n\n* Confirmed diagnosis of tremor due to Parkinson's disease, clinically established, based on the diagnostic criteria of the Movement Disorders Society, and additionally:\n* Tremor associated with bradykinesia of any duration.\n* Confirmatory clinical diagnosis of tremor due to Parkinson's disease (stages 1 to 2 of Hoehn and Yahr) by the neurologist responsible for the participant's follow-up.\n\nGroup 2:\n\n* Confirmed diagnosis of essential tremor, based on the criteria of the Movement Disorders Society, and additionally:\n* Positional tremor plus kinetic and\u002For resting tremor with follow-up in outpatient neurology consultations for at least 3 years without a change in diagnosis.\n* Absence of bradykinesia.\n\nExclusion Criteria:\n\n* Patients undergoing treatment with antipsychotics or antidepressants.\n* Patients with Parkinson's disease and dyskinesias.\n* Patients undergoing treatment with dopaminergic agonists or primidone.\n* Tremor of such severity that it prevents continuous tracing, at the investigator's discretion.\n* Cognitive or affective pathology that limits the ability to collaborate with the study procedures.\n* Participation in another clinical study involving an intervention, procedure, or visit frequency that is incompatible with the present study.\n* Participants diagnosed with any of the following conditions:\n\nAlcoholism of sufficient intensity to influence handwriting or cause neuropathy, at the investigator's discretion. Peripheral neuropathy of any cause. Dystonias. Previous stroke.","45 Years","79 Years",{"count":295,"type":20},110,"In clinical practice, it is sometimes difficult to establish whether a patient's tremor is due to Parkinson's disease or essential tremor. The distinction is crucial as the health implications differ significantly between the two conditions. Therefore, the present study aims to develop a diagnostic method based on machine learning techniques to help differentiate whether a patient's tremor is due to one condition or the other. To achieve this, 110 patients with tremor, correctly diagnosed with either Parkinson's disease or essential tremor, will participate. They will undergo two diagnostic tests (tapping test and Archimedean spiral) to capture data that can be processed using machine learning techniques.",[298,299,300],"Tremor","Essential Tremor","Parkinson Disease",[298,299,300,302,303],"Diagnosis, Differential","Machine Learning",{"date":278,"type":33},{"date":306,"type":33},"2024-07-15",{"date":282,"type":20},{"name":39,"class":40},{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":76,"phases":319,"briefSummary":321,"conditions":322,"keywords":324,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":328,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":41},"100538986","phase-3-acetic-acid-2-solution-for-skin-ulcers-100538986","NCT06297967","Acetic Acid 2% Solution for Skin Ulcers","Acetic Acid in Cutaneous Ulcers. A Randomized Controlled Trial","ECA-AA","Inclusion Criteria:\n\n* Patients over 18 years of age.\n* Continued care (hospital or outpatient) in one of the Consorci Sanitari Alt Penedes i Garraf (CSAPG) units.\n* Presence of a cutaneous ulcer with biofilm, with an area of less than 120 cm2, and in any location (except the facial region).\n* Plan to undergo treatment and follow-up of the lesion (at least 8 weeks) at the study center.\n* Ability to cooperate in necessary evaluations.\n* Informed consent for inclusion in the study, either from the participant themselves or from their legal representative.\n\nExclusion Criteria:\n\n* Participants diagnosed with any of the following conditions:\n\n  1. Ulcers with exposed bone tissue.\n  2. Neoplastic-origin ulcers.\n  3. Ulcers lasting more than 18 months.\n* Participation in another clinical trial involving an experimental intervention during the period of the current trial and\u002For establishing a visit frequency incompatible with the current trial.",{"count":318,"type":20},104,[320],"PHASE3","The objective of this clinical trial is to assess the effectiveness of acetic acid in patients suffering from chronic cutaneous ulcers with biofilm. The primary question it seeks to address is whether acetic acid (as a 2% topical solution) is superior to the current standard treatment for chronic cutaneous ulcers with biofilm at our center (Prontosan®).\n\nParticipants will be randomly assigned to receive either the acetic acid solution treatment or the standard current treatment.",[323],"Ulcer, Skin",[325,326,327],"Skin Ulcer","Acetic Acid","Biofilms",{"date":278,"type":33},{"date":330,"type":33},"2025-04-27",{"date":332,"type":20},"2027-03",{"name":39,"class":40},{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":16,"minAge":342,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":345,"conditions":346,"keywords":348,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":351,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":355,"locationsCount":356},"100476270","neuropsychological-assessment-of-the-oldest-old-populationneuropsic-gr-100476270","NCT05481749","Neuropsychological Assessment Of The Oldest-Old Population.(NEUROPSIC-GR)","Neuropsychological Assessment Of The Non-institutionalized Oldest-Old Population. Multicenter Normative Study.","NEUROPSIC-GR","Inclusion Criteria:\n\n* 80 or more years old\n* Residence at Comarca del Garraf\n* Able to be transfered to study center\n* Sufficient reading and writing capacity to carry out the neuropsychological tests, at the evaluator's discretion.\n\nExclusion Criteria:\n\n* Patient at end-of-life situation or with a very short life expectancy (days-weeks).\n* Hospital admission in the previous 3 months.\n* History of relevant mental illness: major depression, psychosis, bipolar disorder, obsessive-compulsive disorder.\n* Disease of the central nervous system with possible cognitive impairment: Parkinson's disease, multiple sclerosis, brain tumor, stroke with cognitive impairment, epilepsy, severe traumatic brain injury.\n* History of alcoholism or substance abuse.\n* Severe sensory deficit that prevents performing neuropsychological tests, at the discretion of the evaluator.\n* Positive Shortened Spanish Informant Questionnaire for Cognitive Decline in the Elderly questionnaire (SS-IQCODE) or Lobo's Cognitive Mini-examination Test (spanish adaptation of Minimental of Folstein test) with a score \\\u003C 23 (20 in people with low schooling or illiteracy).\n* Dementia criteria according to the Diagnostic and Statistical Manual of Mental Disorders IV.","80 Years",{"count":344,"type":20},120,"Neuropsychological tests currently considered to evaluate the cognitive performance of the oldest-old population (more than 80 years) are not adapted to this group population. This trial aims to determine the normal limits for this group population of a set of 18 neuropsychological test. Results may improve the diagnostic cognitive evaluation of this population.",[229,347],"Cognition Disorders in Old Age",[349,350,229,347],"Geriatric Assessment","Aged, 80 and over",{"date":278,"type":33},{"date":353,"type":33},"2023-02-14",{"date":234,"type":20},{"name":39,"class":40},6,{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":76,"phases":367,"briefSummary":368,"conditions":369,"keywords":371,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":41},"100455383","heparinization-vs-salinization-of-the-peripheral-venous-catheter-100455383","NCT05209841","Heparinization vs Salinization of the Peripheral Venous Catheter","Heparinization vs Salinization of the Peripheral Venous Catheter: a Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients older than 18 yo, admitted to the Hospital Residencia Sant Camil\n* Patients with at least one peripheral venous line for discontinuous treatment, which has not been channeled in a medical emergency situation.\n* Written informed consent\n\nExclusion Criteria:\n\n* Allergy to heparin\n* Patients treated with unfractionated sodium heparin.\n* Patients in dialysis\n* Patients with a venous catheter indicated for diagnosis tests.\n* Patients with a venous catheter indicated for blood transfusion\n* Severe heparin-induced thrombocytopenia in recent months\n* Active uncontrollable bleeding during admission\n* Brain aneurysm or dissecting aorta, except in association with corrective surgery.\n* Confirmed \u002F suspected cerebrovascular hemorrhage\n* Severe uncontrolled hypertension\n* Severe alterations in platelet coagulation \\\u003C30,000, TP\\> 1.7 APTT ratio\\> 1.7 ratio.\n* Patient included in another clinical trial with drugs or procedures that may affect the patency of venous catheters.","100 Years",{"count":366,"type":20},3450,[78],"Randomized, double-blind clinical trial to compare the efficacy of catheter sealing with saline, compared to low-dose heparin. 3,450 patients hospitalized at the Hospital Residencia Sant Camil, in Catalonia (Spain), will be randomized to each branch of study. The primary outcome will be the percentage of catheters removed due to obstruction in each branch of study. As secondary outcomes, the number of catheter-associated phlebitis, catheter-associated bacetrihemia, extravasation, and catheter loss will be measured. For the primary outcome, a superiority analysis will be carried out in terms of the percentage of obstructed catheters in each branch of the study.",[370],"Catheter Complications",[372,373],"Catheterization, Peripheral","Catheter Obstruction",{"date":375,"type":33},"2025-06-25",{"date":377,"type":33},"2022-04-05",{"date":379,"type":20},"2026-07-30",{"name":39,"class":40},{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":76,"phases":391,"briefSummary":392,"conditions":393,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":395,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":258},"100446495","open-label-randomized-clinical-trial-to-assess-the-safety-of-teleconsultation-100446495","NCT05094180","Open Label Randomized Clinical Trial to Assess the Safety of Teleconsultation","Open Label Randomized Clinical Trial to Assess the Safety of Teleconsultation, Compared to the Traditional Clinical Consultation","ECASeT","Inclusion Criteria:\n\n* Men and women of any age.\n* Possibility of making consultations by telephone, at the discretion of the investigator, taking into account the severity and complexity of the baseline pathology and the objective of health care.\n* Forecast to carry out follow-up in external consultation.\n* Agreement to be attended through a non-face-to-face system.\n* Ability to connect to the video consultation system.\n* Device compatible with the video consultation system.\n* Possibility of collaborating in the necessary evaluations.\n* Legal capacity to give informed consent.\n* Signature of the informed consent for inclusion of the study.\n\nExclusion Criteria:\n\n* Need to carry out physical examinations, visualize the patient in person or perform techniques that involve face-to-face visits.\n* Need for face-to-face consultation due patient's clinical situation.\n* Follow-up by more than three medical specialists.\n* Visual, hearing or functional impairments that may hamper patient-physician communication.\n* Patients enrolled in another clinical trial that requires an experimental intervention during the follow-up.",{"count":390,"type":20},2136,[78],"Randomized-controlled trial to assess the safety of remote consultations (both video and teleconsultation) in the follow-up of patients in the hospital setting. A total of 2136 patients will be randomly allocated into one of the three study arms: A) face-to-face consultation (control) B) Remote consultation (telephone or video consultation). Primary outcome will be the frequency of complications of the underlying disease, including adverse reactions to the treatment of the underlying disease.\n\nTo be eligible for remote consultation, patients have to have adequate digital literacy at physician discretion, technological capacity to use the video conferencing software, and undergo a type of follow-up that, due to the moderate complexity of the pathology, do not require physical examinations. Patients followed up in more than three departments, those with visual or hearing impairments that may hamper patient-physician communication, and those enrolled in another clinical trial that requires an experimental intervention during the follow-up will be excluded from the study.\n\nPhysicians can schedule and cancel appointments at their discretion. At least three visits should be scheduled in the study setting: the baseline visit (i.e., screening visit), intermediate visits (pre-defined by the physician based on the follow-up needed for managing the baseline condition), and the final visit (i.e., either the follow-up visit closest to 12 ± 2 months after enrollment or before in case of discharge or early discontinuation).\n\nThe primary objective will be assessed using a non-inferiority analysis of the cumulative incidence of complications of the baseline disease between remote consultation (video and teleconsultation arms) and face-to-face consultation, using a non-inferiority margin of 2%. The analysis will be based on a modified binomial test to assess the non-inferiority of an experimental intervention vs. a control group in a three-arm trial. The primary analysis will be conducted on a per-protocol study sample, which will include all participants who have finished the study and have not been withdrawn because of non-allowed visits using modalities other than scheduled.",[394],"Various Clinical Conditions Commonly Followed up in a Secondary Hospital",{"date":375,"type":33},{"date":397,"type":33},"2021-12-01",{"date":399,"type":20},"2026-12-31",{"name":39,"class":40},{"id":402,"slug":403,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":76,"phases":411,"briefSummary":412,"conditions":413,"keywords":416,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":41},"100566107","desarda-tissue-technique-vs-lichtenstein-technique-for-primary-inguinal-hernia-repair-100566107","NCT06650878","Desarda Tissue Technique vs Lichtenstein Technique for Primary Inguinal Hernia Repair","Randomized Controlled Trial Comparing the Desarda Tissue Technique With the Lichtenstein Technique in Primary Inguinal Hernia Repair","HP-tis","Inclusion Criteria:\n\n* Diagnosed with primary inguinal hernia.\n* Body mass index below 31\n* Indication for inguinal hernia repair via anterior approach, either as outpatient surgery (CMA) or elective admission.\n* Legal capacity to provide informed consent.\n\nExclusion Criteria:\n\n* Patients with a weak, thin, or divided external oblique aponeurosis.\n* Participants diagnosed with any of the following conditions:\n\n  * Ongoing oncological disease\n  * Cirrhotic patients classified as Child B or higher\n* Women who have previously undergone a cesarean section\n* Cognitive or affective conditions that limit the ability to cooperate with the study procedures",{"count":410,"type":20},478,[78],"This study aims to evaluate whether a surgical technique (Desarda) is superior to the commonly used surgical technique (Lichtenstein) in inguinal hernia repair concerning the occurrence of postoperative complications. The Lichtenstein technique involves the use of a mesh, while the Desarda technique does not.",[414,415],"Inguinal Hernia Unilateral","Complications of Surgical Procedures or Medical Care",[417,418,419],"Inguinal Hernia","lichtenstein technique","desarda technique","2025-06-18",{"date":422,"type":33},"2025-06-24",{"date":424,"type":33},"2025-03-26",{"date":426,"type":20},"2030-12-01",{"name":39,"class":40},{"id":429,"slug":430,"hasResults":11,"nctId":431,"briefTitle":432,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":434,"enrollmentInfo":435,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":437,"conditions":438,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":446,"locationsCount":41},"100571755","detection-of-health-risk-situations-in-the-anesthesia-consultation-100571755","NCT06724380","Detection of Health Risk Situations in the Anesthesia Consultation.","Inclusion Criteria:\n\n* Men and women aged 18 to 50 years.\n\n  * Indication for elective surgery.\n  * In-person preoperative evaluation in the scheduled Anesthesiology consultation.\n\nExclusion Criteria:\n\n* Indication for non-deferrable urgent surgery.\n* Pregnant women.\n* Pre-surgical visit outside the anesthesia consultation.\n* Incomplete preoperative evaluation, as indicated in the final section (preoperative judgment) of the anesthesia visit report.","50 Years",{"count":436,"type":20},218,"This study aims to estimate the proportion of patients seen in the anesthesiology consultation for planned surgery in whom a previously unknown health risk situation is detected (e.g., obesity, anemia, etc.).",[439],"Surgical Procedures, Operative","2025-02-10",{"date":442,"type":33},"2025-02-12",{"date":444,"type":33},"2025-02-04",{"date":137,"type":20},{"name":39,"class":40},{"id":448,"slug":449,"hasResults":11,"nctId":450,"briefTitle":451,"officialTitle":451,"acronym":452,"eligibilityCriteria":453,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":342,"enrollmentInfo":454,"targetDuration":4,"studyType":76,"phases":455,"briefSummary":456,"conditions":457,"keywords":459,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":462,"startDateStruct":463,"completionDateStruct":464,"leadSponsor":466,"locationsCount":41},"100546382","benefit-of-a-hospital-intervention-in-patients-with-hepatic-steatosis-100546382","NCT06394206","Benefit of a Hospital Intervention in Patients With Hepatic Steatosis","BIPEH","Inclusion Criteria:\n\n* Patients seen in outpatient gastroenterology clinics with hepatic steatosis.\n* Diagnosed with hepatic steatosis through ultrasound or abdominal CT scan\n* Mild to moderate fibrosis as assessed by elastography or FibroScan (F1-F3) or with a Fibrosis-4 (FIB-4) Index less than 3.5.\n* Signature of informed consent for study inclusion, either by the participant themselves or by their legal representative.\n\nExclusion Criteria:\n\n* Patients who do not have any hepatic imaging test conducted in the last 5 years.\n* Conditions other than hepatic steatosis requiring gastroenterological follow-up.\n* Abusive alcohol consumption, defined as weekly intake of \\> 50 g in women and more than 70 g in men.\n* Cognitive or affective disorders limiting the ability to cooperate with study procedures.\n* Participation in another clinical trial involving experimental intervention during the period of this trial and\u002For establishing visit schedules incompatible with this trial.",{"count":75,"type":20},[78],"The objective of this clinical trial is to determine whether a specialized consultation for controlling metabolic syndrome effectively treats hepatic steatosis in adults. The primary questions it aims to answer are:\n\n• Does this specialized consultation increase the number of patients with hepatic steatosis who show improvement after one year of clinical follow-up in said consultation?\n\nThe improvement of the disease will be assessed through the following parameters:\n\n* liver laboratory tests\n* weight loss\n* improvement in cholesterol and triglyceride levels. Researchers will compare follow-up in the specialized consultation to standard follow-up to assess the effectiveness of the specialized consultation in treating hepatic steatosis.\n\nParticipants will be randomly assigned to two groups. The first group will be visited in the specialized consultation every three months for one year and will continue to receive the rest of their follow-up visits. The second group will undergo their usual follow-up visits but will not be visited in the specialized consultation.",[458],"Hepatic Steatosis",[460,461],"Fatty Liver","Metabolic Syndrome",{"date":442,"type":33},{"date":137,"type":20},{"date":465,"type":20},"2027-12",{"name":39,"class":40},""]